Stock and Other Ownership Interests: PathomIQ, Arxeon Therapeutics (I) Consulting or Advisory Role: Seattle Genetics, Bayer, Boehringer Ingelheim, Mundipharma EDO GmbH, Harbour BioMed, SpringWorks Therapeutics, Gilead Sciences, Mirati Therapeutics, EcoR1 Capital, Cadila Pharmaceuticals (I), Oxford BioTherapeutics. Cancer Early Detection Advanced Research Center, Adolescent and Young Adult Oncology Program, Social and Emotional Side Effects of Cancer, International Alliance for Early Cancer Detection (ACED), Lisa M. Coussens, M.D. Spray Foam Equipment and Chemicals. Increasing patient participation in oncology clinical trials, A Novel Artificial IntelligencePowered Method for Prediction of Early Recurrence of Prostate Cancer after Prostatectomy and Cancer Drivers, Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas, Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer. General Information Email: [email protected], Mailing Address Shivaani Kummar Professor Professor, Knight Cancer Institute Knight Cancer Translational Oncology Program Email kummar @ ohsu. (44 Ratings, 1 - 20 out of 67 Results for "Shivaani Kummar" 67 Results Select All . To find better ways to treat patients. Administrative Coordinator, Karri Garaventa Home; NPI Lookup; Doctors; Medical Groups & Orgs; Taxonomy Codes; Lookup NPI Numbers from the NPI Registry . The patient ratings score is an average of all responses to the question "How likely would you be to recommend this provider to your family and friends (on a scale of 0 to 10)" on our nationally-recognized NRC patient surveys. BYLINE. Our new center will foster collaboration across disciplines, bringing together investigators interested in developing new treatments, Malhotra says. Support the Abortion Care and Training Fund. 2001-2022 Oregon Health & Science University. . Division head of medical oncology Shivaani Kummar, M.D., FACP Accepting new patients Division head of radiation medicine Arthur Y. Learn more about clinical trials at the Knight Cancer Institute, The 13,000-square-foot early-phase research unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. (h.c.), Ph.D., FAACR. Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials. Most recently, he was the director for Stanford SRI Drug Discovery and Development Program, and he trained with Nobel laureate Herb Brown at Purdue University. February 17, 2023. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. . L Fong, A Hotson, JD Powderly, M Sznol, RS Heist, TK Choueiri, S Kummar, A Chen, RE Parchment, RJ Kinders, J Ji, JE Tomaszewski, AF Farago, MS Taylor, RC Doebele, VW Zhu, S Kummar, AI Spira, S Kummar, M Gutierrez, ER Gardner, E Donovan, K Hwang, EJ Chung, Clinical Cancer Research 13 (18), 5411-5417. This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. Visit thebilling andinsurancesection of our sitefor more information. Office 3181 SW Sam Jackson Park Rd Portland, OR 97239 Phone+1 503-280-1223 Is this information wrong? 23() 'Oregon Health & Science University Knight Cancer Institute(OHSU)' BAL0891 1 Shivaani Kummar (Principal Investigator, PI), OHSU 'Mary Crowley Cancer Research . Dr. Shivaani Kummar is an oncologist practicing in Bethesda, MD. Keep me signed in. (OHSU/Joe Rojas-Burke). These new drugs go through very rigorous testing in the laboratory and only if they meet certain criteria as promising anticancer agents, we bring them forward into the first phase of human clinical trials. Each faculty member comes with a unique background, which often propels him or her into medicine and a particular . Then we try to find what we call targets within or around cancer cells and develop drugs that can precisely hit those targets. She received her medical degree from Lady Hardinge Medical College and has been in practice for . Professor of Medicine, OHSU. OHSU researchers lead innovation and passion through new discoveries, comradery of the OHSU research community and the drive to improve peoples health and well-being. Dr. Clinical trials are research studies that test how well new medicines or treatments work in people. The center is designed to advance innovation efforts within the Knight Cancer Institute to discover and develop new treatments for cancer, from early phase clinical trials, to drug development. Shivaani Kummar 1 2 , Apurva K Srivastava 3 , Tony Navas 3 4 , Fabiola Cecchi 5 6 , Young H Lee 5 7 , Donald P Bottaro 5 , Sook Ryun Park 1 8 , Khanh T Do 1 9 , Woondong Jeong 1 10 , Barry C Johnson 1 , Andrea R Voth 1 , Larry Rubinstein 11 , John J Wright 1 , Ralph E Parchment 3 , James H Doroshow 1 12 , Alice P Chen 13 Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. Malhotras impressive background in drug development will be key to cultivating this new center, says Druker, also the JELD-WEN Chair of Leukemia Research at OHSU. Local: (503) 228-1730 | Toll Free: (800) 462-6608 By using this website, we will assume that you agree to the terms and conditions of our privacy policy. condition, procedure, doctor name. For help with all referral needs and questions, visit Referring Physicians. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. This conversation is with Shivaani Kummar, MD (professor, oncology), who joined the Stanford faculty in January 2015. 1. cleveland, tx funeral homes share dancing on ice app for ipad tweet exhaustive list of cushing's syndrome symptoms share. Cancer and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Blood Diseases, Cancer and Blood Disorders, Hematology and Oncology, Cancer, Cancer and Blood Disorders and Benign Blood Disorders, Cancer, Hematology Oncology and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Medical Oncology and Hematology, Cancer, Blood Diseases and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Bladder Cancer, Cancer, Hematology Oncology and Blood Cancers, Hospice and Palliative Care, Internal Medicine and Psychiatry, Hospice and Palliative Care and Palliative Care, Hospice and Palliative Care, Internal Medicine and Geriatrics, Sarah Lowry, D.N.P., ACNP-BC, AOCNP, ACHPN, Thomas G. DeLoughery, M.D., M.A.C.P., FAWM. She co-leads a team of 90 faculty members and along with her husband, Sanjay Malhotra, PhD, is focused on discovering new therapies for cancer and giving more people access to safe, experimental cancer treatments. Expanding scientific knowledge is a key mission of OHSU, Oregons only academic health center. SHIVAANI KUMMAR, 207RX0202X - Medical Oncology Doctors & Physicians in PORTLAND, OR. Equipment. Accepting new patients Their partnership will be a perfect pairing.. Shivaani Kummar (OHSU) [email protected] Upon completing her medical degree from Lady Hardinge Medical College in New Delhi, India, Shivaani Kummar moved to the United States to train in Internal Medicine at Emory University in Atlanta, Georgia. In 2014, the state of Oregon supported the OHSU Knight Cancer Challenge by providing $200 million in bonding to support building cancer research and clinical trial capacity. As an oncologist, Dr. Kummar manages and oversees the treatment of a cancer patient after he or she has been diagnosed with the disease. Caring for them drives me to work harder to develop more effective treatments that are better tolerated. . Try restaurant style recipes at home. Our ability to collaborate with academics and industries across the globe will be paramount to our success in developing new drugs for patients. Trisha Silbernagel, RN, BSN, early-phase clinical trial unit manager, checks equipment on Aug. 23, 2021. Shivaani Kummar: STUDY00022986: An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer . OHSU HOSPITAL AND CLINICS: 380009: Provider Business Practice Location Address Details: Address: 3181 Sw Sam Jackson Park Rd, City: Portland . Shivaani Kummar (Principal Investigator, PI). OHSU 'Mary Crowley Cancer . Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute, speaks with staff members on Aug. 23, 2021. NPI Lookup NPI Database. The OHSU Knight Cancer Institute is part of regional, national and international research partnerships, offering patients local access to the latest advances and clinical trials. Sort. 2001-2023 OHSU. The institute is involved with more than 400 clinical trials, including 113 early-phase trials. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Within our Center for Experimental Therapeutics, Knight Cancer Institute, we have multiple ongoing projects trying to identify new ways to target cancer. OHSU Foundation P.O. 2001-2023 OHSU. Want to join the faculty at the Knight Cancer Institute? Hamburger Menu x Home A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. Response to treatment was evaluated at cycle 1 and every six cycles, that is, 18 weeks, by RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. Philanthropy will allow us to expand the number of ongoing projects, including those focusing on rare tumors, as well as take on more pre- and post-doctoral students to train the next generation of cancer researchers. Dr. The new early-phase research unit completes this expansion in the building. OHSU is an equal opportunity affirmative action institution. Shivaani Kummar (Principal Investigator, PI), OHSU Mary Crowley Cancer Research, Montefiore Medical Center 4 1 . Patients and Methods. . We are proud to be able to offer our patients access to the most advanced cancer therapies available, said Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institutes Center for Experimental Therapeutics.